India In Talks With Moderna Over 94.5% Vaccine Efficacy Proof
India In Talks With Moderna: The US biotech giant Moderna Therapeutics has confirmed that its Covid-19 vaccine sample guarantees a 94.5% success rate in its phase 3 efficacy trials. The Indian government is apparently in talks with the company over the development of the company’s vaccine candidate.
According to a senior government official, “India is keeping its options open and is in discussions with both Indian and international players in the market for developing an effective Covid-19 vaccine. Communication is on with Pfizer, Serum Institute, Bharat Biotech and Zydus Cadila for their Covid-19 vaccine candidate in terms of safety, immunogenicity and efficacy.”
Indeed, Moderna claims five percent more efficacy over its American counterpart Pfizer and Germany’s BioNTech. On its part, Moderna has made an official statement claiming that, “The NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against Covid-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5 per cent.”
India is in the race of developing its own vaccine and has vowed to share the formula widely with the other nations.